Beyond Randomized Clinical Trials: Use of External Controls. Issue 4 (17th December 2019)

• Record Type: Journal Article
• Authors: Schmidli, Heinz; Häring, Dieter A.; Thomas, Marius; Cassidy, Adrian; Weber, Sebastian; Bretz, Frank
• Is Part Of: Clinical pharmacology & therapeutics. Volume 107:Issue 4(2020)
• Page Start: 806
• Page End: 816
• Publication Date: 2019-12-17
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.1723
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : Randomized controlled trials are the gold standard to investigate efficacy and safety of new treatments. In certain settings, however, randomizing patients to control may be difficult for ethical or feasibility reasons. Borrowing strength using relevant individual patient data on control from external trials or real‐world data (RWD) sources may then allow us to reduce, or even eliminate, the concurrent control group. Naive direct use of external control data is not valid due to differences in patient characteristics and other confounding factors. Instead, we suggest the rigorous application of meta‐analytic and propensity score methods to use external controls in a principled way. We illustrate these methods with two case studies: (i) a single‐arm trial in a rare cancer disease, using propensity score matching to construct an external control from RWD; (ii) a randomized trial in children with multiple sclerosis, borrowing strength from past trials using a Bayesian meta‐analytic approach.